Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


First-timer resumes PBAC fight

Posted 22 February 2021 PM

After registering its first product in Australia this month, Kyowa Kirin has confirmed it will continue to pursue reimbursement for Poteligeo despite already being rejected twice by the PBAC.

Prior to the TGA's approval, the medicine had been knocked back at the PBAC's July meeting and November meeting in 2020 for two rare forms of lymphoma - mycosis fungoides and Sezary syndrome.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pitfalls may plague NMP review
With an election in play, will it arrive too late?
Approvals Action
First copy of Halaven ticked
Along with other generics of already PBS-listed drugs